Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New cocktail hopes to tame tough pancreatic cancer

NCT ID NCT05026905

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This phase II trial is testing two different drug combinations for people with metastatic pancreatic cancer that has spread. One group gets a standard chemo plus S-1 and leucovorin; the other gets standard chemo plus oxaliplatin. The goal is to see which combo works better at shrinking tumors and delaying progression. About 66 participants are enrolled across multiple centers in Taiwan.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
gemcitabine, nab-paclitaxel, S-1, leucovorin, oxaliplatin
What this could lead to
If successful, this could point toward a more effective first-line treatment for metastatic pancreatic cancer, potentially extending the time patients live without the disease worsening.
What could go wrong
This is a small, early-phase trial (66 participants) testing two experimental combinations. The results may not lead to a new standard of care, and the added drugs could increase side effects without improving survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 66 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2021

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * A.Cytology or histology confirmed pancreatic adenocarcinoma with evidence of distant metastasis.Mixed component of other cell type (eg, adenosquamous, adenocarcinoma with neuroendocrine differentiation) is eligible but should notify PI before registration. * B.No history of prior chemotherapy for pancreatic cancer, except adjuvant chemotherapy that completed at least 6 months before documentation of recurrence by imaging study. * C.Patients with prior radiotherapy are eligible if there are other measurable target lesions that is not irradiated. * D.At least one measurable lesion according to RECIST version 1.1 * E.Ability to understand and willingness to sign a written informed consent document. * F.ECOG performance status 0-1 * G.Age of 20 years or above * H.Adequate organ function as defined by the following criteria: absolute neutrophil count (ANC) ≥ 1,500/mm3 hemoglobin level ≥ 9 g/dL platelet count ≥ 100,000/mm3 total bilirubin ≤ 2 ULN or ≤5 ULN if caused by biliary obstruction and achieving adequate drainage judged by investigator aspartate aminotransferase (AST) / alanine aminotransferase (ALT) ≤ 3 x ULN or ≤ 5.0×ULN in the presence of liver metastases creatinine clearance rate (CCr) ≥ 50 mL/min (24-hour urine collection or calculated by Cockroft-Gault formula; male: \[(140 - age) × weight (kg)\]/\[72 × serum creatinine(mg/dL)\];female=male x 0.85 -I.Patients with childbearing potential shall have effective contraception for both the patient and his or her partner during the study. Exclusion Criteria: * A. Other malignancy within the past 5 years except for adequately treated localized cancer or carcinoma in situ;All patients with other malignancy within the past 5 years should notify PI before registration. * B.Active or uncontrolled infection; * C.Significant medical conditions that is contraindicated to study medication or render patient at high risk from treatment complications at physician discretion * D.Pregnant women or nursing mothers, or positive pregnancy test for women of childbearing potential. * E.History of active autoimmune disease within 3 years or use of steroid more than prednisolone 10mg/day.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic pancreatic adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • China Medical University Hospital

    Taichung, 400, Taiwan

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, 800, Taiwan

  • National Cheng Kung University Hospital

    Tainan, 600, Taiwan

  • Taichung Veterans General Hospital

    Taichung, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.